ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,969.01
-0.16%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Elevation Oncology Inc (ELEV)

  7. Elevation Oncology Inc (ELEV) Noticias

ELEV

Elevation Oncology (ELEV)

Elevation Oncology Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ELEV
FechaHoraFuenteTítuloSímboloCompañía
17/05/202415:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
09/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELEVElevation Oncology Inc
09/05/202415:39Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELEVElevation Oncology Inc
07/05/202406:30PR Newswire (US)Elevation Oncology to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:ELEVElevation Oncology Inc
02/05/202406:30PR Newswire (US)Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
08/04/202415:30PR Newswire (US)Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
06/03/202407:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELEVElevation Oncology Inc
06/03/202406:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
06/03/202406:30PR Newswire (US)Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/03/202406:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ELEVElevation Oncology Inc
05/03/202415:50PR Newswire (US)Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
04/03/202415:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
04/03/202406:30PR Newswire (US)Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
28/02/202406:30PR Newswire (US)Elevation Oncology to Participate in Upcoming Investor ConferencesNASDAQ:ELEVElevation Oncology Inc
22/02/202406:30PR Newswire (US)Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanNASDAQ:ELEVElevation Oncology Inc
14/02/202415:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELEVElevation Oncology Inc
22/01/202415:57Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELEVElevation Oncology Inc
22/01/202406:30PR Newswire (US)Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
05/01/202406:30PR Newswire (US)Elevation Oncology Announces Program Updates and Upcoming 2024 MilestonesNASDAQ:ELEVElevation Oncology Inc
22/11/202306:30PR Newswire (US)Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:ELEVElevation Oncology Inc
02/11/202306:30PR Newswire (US)Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
02/11/202306:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELEVElevation Oncology Inc
05/09/202306:30PR Newswire (US)Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ELEVElevation Oncology Inc
16/08/202306:30PR Newswire (US)Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021NASDAQ:ELEVElevation Oncology Inc
03/08/202306:30PR Newswire (US)Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
03/08/202306:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELEVElevation Oncology Inc
13/07/202307:00PR Newswire (US)Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial OfficerNASDAQ:ELEVElevation Oncology Inc
21/06/202315:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ELEVElevation Oncology Inc
20/06/202315:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ELEVElevation Oncology Inc
15/06/202315:31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ELEVElevation Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:ELEV

Su Consulta Reciente

BIT
P1T5O0
BNP Paribas Issuance
HITB
CUSUSDT
Cushion Coin
LSE
AMST
TSX
IUAE
Invesco S&P US Dividend ...
EU
VUB35
Vrije Universiteit Brussel
LSE
REVB
Revolution Beauty
TSXV
EST
LSE
JUB
NASDAQ
DEACU
Diamond Eagle Acquisition
BIT
P15IT4
BNP Paribas Issuance
BIT
I06573
Banca Imi
BIT
S27022
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados